Skip to main content
Erschienen in: Digestive Diseases and Sciences 8/2016

01.04.2016 | Review

Diagnosis and Surveillance of Barrett’s Esophagus: Addressing the Transatlantic Divide

verfasst von: Saad Ghaus, Helmut Neumann, Humayun Muhammad, Gian Eugenio Tontini, Sauid Ishaq

Erschienen in: Digestive Diseases and Sciences | Ausgabe 8/2016

Einloggen, um Zugang zu erhalten

Abstract

Background

Barrett’s esophagus is a premalignant condition of the esophagus leading to esophageal adenocarcinoma. No consensus exists between the UK and USA concerning the diagnosis of Barrett’s esophagus. Although the diagnostic procedure is common, the required findings and diagnostic criteria vary. Both guidelines require endoscopy showing columnar epithelia lining the esophagus, but the US guidelines require the additional finding of intestinal metaplasia on biopsy to confirm diagnosis. Achievement of a consensus is of particular importance due to the established progression from Barrett’s esophagus to esophageal adenocarcinoma. Of further importance is the increasing incidence of esophageal adenocarcinoma, a condition with poor overall survival, leading to various opinions on the utility of surveillance in patients.

Discussion

A review of the vast array of literature revealed that substantial evidence exists in favor of both diagnostic criteria; hence, there is no easy way to identify the “correct” method of diagnosing Barrett’s esophagus. USA recommends surveillance of Barrett’s esophagus, whereas UK does not advocate it unless dysplasia is present. Surveillance was found to be effective, but this varied as did cost-effectiveness.

Summary

Further research into diagnostic methods for Barrett’s esophagus is needed to address areas of limited understanding, such that agreement can be reached and practice standardized. Surveillance was generally advocated, but with different criteria and time intervals, and new methods are being evaluated.
Literatur
2.
Zurück zum Zitat Dulai GS, Guha S, Kahn KL, Gornbein J, Weinstein WM. Preoperative prevalence of Barrett’s esophagus in esophageal adenocarcinoma: a systematic review. Gastroenterology. 2002;122:26–33.CrossRefPubMed Dulai GS, Guha S, Kahn KL, Gornbein J, Weinstein WM. Preoperative prevalence of Barrett’s esophagus in esophageal adenocarcinoma: a systematic review. Gastroenterology. 2002;122:26–33.CrossRefPubMed
4.
Zurück zum Zitat Coleman HG, Bhat S, Murray LJ, McManus D, Gavin AT, Johnston BT. Increasing incidence of Barrett’s oesophagus: a population-based study. Eur. J. Epidemiol. 2011;26:739–745.CrossRefPubMed Coleman HG, Bhat S, Murray LJ, McManus D, Gavin AT, Johnston BT. Increasing incidence of Barrett’s oesophagus: a population-based study. Eur. J. Epidemiol. 2011;26:739–745.CrossRefPubMed
5.
Zurück zum Zitat Devesa SS, Blot WJ, Fraumeni JF Jr. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer. 1998;83:2049–2053.CrossRefPubMed Devesa SS, Blot WJ, Fraumeni JF Jr. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer. 1998;83:2049–2053.CrossRefPubMed
6.
Zurück zum Zitat Corley DA, Kubo A, Levin TR, et al. Abdominal obesity and body mass index as risk factors for Barrett’s esophagus. Gastroenterology. 2007;133:34–41. (quiz 311).CrossRefPubMed Corley DA, Kubo A, Levin TR, et al. Abdominal obesity and body mass index as risk factors for Barrett’s esophagus. Gastroenterology. 2007;133:34–41. (quiz 311).CrossRefPubMed
7.
Zurück zum Zitat Brown LM, Devesa SS. Epidemiologic trends in esophageal and gastric cancer in the United States. Surg. Oncol. Clin. N. Am. 2002;11:235–256.CrossRefPubMed Brown LM, Devesa SS. Epidemiologic trends in esophageal and gastric cancer in the United States. Surg. Oncol. Clin. N. Am. 2002;11:235–256.CrossRefPubMed
8.
Zurück zum Zitat Aida J, Vieth M, Shepherd N, et al. Is carcinoma in columnar-lined esophagus always located adjacent to intestinal metaplasia? Am. J. Surg. Pathol. 2015;39:188–196.CrossRefPubMed Aida J, Vieth M, Shepherd N, et al. Is carcinoma in columnar-lined esophagus always located adjacent to intestinal metaplasia? Am. J. Surg. Pathol. 2015;39:188–196.CrossRefPubMed
9.
Zurück zum Zitat Alvarez Herrero L, Curvers W, van Vilsteren F, et al. Validation of the Prague C&M classification of Barrett’s esophagus in clinical practice. Endoscopy. 2013;45:876–882.CrossRefPubMed Alvarez Herrero L, Curvers W, van Vilsteren F, et al. Validation of the Prague C&M classification of Barrett’s esophagus in clinical practice. Endoscopy. 2013;45:876–882.CrossRefPubMed
10.
Zurück zum Zitat Armstrong D. Review article: towards consistency in the endoscopic diagnosis of barrett’s oesophagus and columnar metaplasia. Aliment. Pharmacol. Ther. 2004;20:40–47.CrossRefPubMed Armstrong D. Review article: towards consistency in the endoscopic diagnosis of barrett’s oesophagus and columnar metaplasia. Aliment. Pharmacol. Ther. 2004;20:40–47.CrossRefPubMed
11.
Zurück zum Zitat Hoshihara Y, Kogure T. What are longitudinal vessels? Endoscopic observation and clinical significance of longitudinal vessels in the lower esophagus. Esophagus. 2006;3:145–150.CrossRef Hoshihara Y, Kogure T. What are longitudinal vessels? Endoscopic observation and clinical significance of longitudinal vessels in the lower esophagus. Esophagus. 2006;3:145–150.CrossRef
12.
Zurück zum Zitat American Gastroenterological Association, Spechler SJ, Sharma P, Souza RF, Inadomi JM, Shaheen NJ. American gastroenterological association medical position statement on the management of barrett’s esophagus. Gastroenterology. 2011;140:1084–1091.CrossRef American Gastroenterological Association, Spechler SJ, Sharma P, Souza RF, Inadomi JM, Shaheen NJ. American gastroenterological association medical position statement on the management of barrett’s esophagus. Gastroenterology. 2011;140:1084–1091.CrossRef
13.
Zurück zum Zitat Repaka A, Chak A. Endoscopic management of Barrett esophagus. Nat. Rev. Gastroenterol. Hepatol. 2011;8:582–591.CrossRefPubMed Repaka A, Chak A. Endoscopic management of Barrett esophagus. Nat. Rev. Gastroenterol. Hepatol. 2011;8:582–591.CrossRefPubMed
14.
Zurück zum Zitat Sharma P, Brill J, Canto M, et al. White Paper AGA: advanced imaging in Barrett’s Esophagus. Clin. Gastroenterol. Hepatol. 2015;13:2209–2218.CrossRefPubMed Sharma P, Brill J, Canto M, et al. White Paper AGA: advanced imaging in Barrett’s Esophagus. Clin. Gastroenterol. Hepatol. 2015;13:2209–2218.CrossRefPubMed
15.
Zurück zum Zitat Paull A, Trier JS, Dalton MD, Camp RC, Loeb P, Goyal RK. The histologic spectrum of Barrett’s esophagus. N. Engl. J. Med. 1976;295:476–480.CrossRefPubMed Paull A, Trier JS, Dalton MD, Camp RC, Loeb P, Goyal RK. The histologic spectrum of Barrett’s esophagus. N. Engl. J. Med. 1976;295:476–480.CrossRefPubMed
16.
Zurück zum Zitat Liu W, Hahn H, Odze RD, Goyal RK. Metaplastic esophageal columnar epithelium without goblet cells shows DNA content abnormalities similar to goblet cell-containing epithelium. Am. J. Gastroenterol. 2009;104:816–824.CrossRefPubMedPubMedCentral Liu W, Hahn H, Odze RD, Goyal RK. Metaplastic esophageal columnar epithelium without goblet cells shows DNA content abnormalities similar to goblet cell-containing epithelium. Am. J. Gastroenterol. 2009;104:816–824.CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Faller G, Borchard F, Ell C, et al. Histopathological diagnosis of Barrett’s mucosa and associated neoplasias: results of a consensus conference of the Working Group for Gastroenterological Pathology of the German Society for Pathology on 22 September 2001 in Erlangen. Virchows Archiv. 2003;443:597–601. doi:10.1038/ajg.2015.116.CrossRefPubMed Faller G, Borchard F, Ell C, et al. Histopathological diagnosis of Barrett’s mucosa and associated neoplasias: results of a consensus conference of the Working Group for Gastroenterological Pathology of the German Society for Pathology on 22 September 2001 in Erlangen. Virchows Archiv. 2003;443:597–601. doi:10.​1038/​ajg.​2015.​116.CrossRefPubMed
18.
Zurück zum Zitat Curvers WL, ten Kate FJ, Krishnadath KK, et al. Low-grade dysplasia in Barrett’s esophagus: overdiagnosed and underestimated. Am. J. Gastroenterol. 2010;105:1523–1530.CrossRefPubMed Curvers WL, ten Kate FJ, Krishnadath KK, et al. Low-grade dysplasia in Barrett’s esophagus: overdiagnosed and underestimated. Am. J. Gastroenterol. 2010;105:1523–1530.CrossRefPubMed
19.
Zurück zum Zitat Weinstein WM, Ippoliti AF. The diagnosis of Barrett’s esophagus: goblets, goblets, goblets. Gastrointest. Endosc. 1996;44:91–95.CrossRefPubMed Weinstein WM, Ippoliti AF. The diagnosis of Barrett’s esophagus: goblets, goblets, goblets. Gastrointest. Endosc. 1996;44:91–95.CrossRefPubMed
20.
Zurück zum Zitat Shaheen N, Falk G, Iyer P, Gerson L. ACG clinical guideline: diagnosis and management of Barrett’s Esophagus. Am. J. Gastroenterol. 2016;111:30–50.CrossRefPubMed Shaheen N, Falk G, Iyer P, Gerson L. ACG clinical guideline: diagnosis and management of Barrett’s Esophagus. Am. J. Gastroenterol. 2016;111:30–50.CrossRefPubMed
21.
Zurück zum Zitat Fitzgerald R, Di Pietro M, Ragunath K, et al. British Society of Gastroenterology guidelines on the diagnosis and management of Barrett’s oesophagus. Gut. 2014;63:7–42.CrossRefPubMed Fitzgerald R, Di Pietro M, Ragunath K, et al. British Society of Gastroenterology guidelines on the diagnosis and management of Barrett’s oesophagus. Gut. 2014;63:7–42.CrossRefPubMed
22.
Zurück zum Zitat Khandwalla H, Graham D, Kramer J, et al. Corrigendum: Barrett’s Esophagus suspected at endoscopy but no specialized intestinal metaplasia on biopsy, what’s next? Am. J. Gastroenterol. 2014;109:1123.CrossRef Khandwalla H, Graham D, Kramer J, et al. Corrigendum: Barrett’s Esophagus suspected at endoscopy but no specialized intestinal metaplasia on biopsy, what’s next? Am. J. Gastroenterol. 2014;109:1123.CrossRef
23.
Zurück zum Zitat Harrison R, Perry I, Haddadin W, et al. Detection of intestinal metaplasia in Barrett’s esophagus: an observational comparator study suggests the need for a minimum of eight biopsies. Am. J. Gastroenterol. 2007;102:1154–1161.CrossRefPubMed Harrison R, Perry I, Haddadin W, et al. Detection of intestinal metaplasia in Barrett’s esophagus: an observational comparator study suggests the need for a minimum of eight biopsies. Am. J. Gastroenterol. 2007;102:1154–1161.CrossRefPubMed
24.
Zurück zum Zitat Kelty C, Gough M, Van Wyk Q. Barrett’s oesophagus: intestinal metaplasia is not essential for cancer risk. Scand. J. Gastroenterol. 2007;42:1271–1274.CrossRefPubMed Kelty C, Gough M, Van Wyk Q. Barrett’s oesophagus: intestinal metaplasia is not essential for cancer risk. Scand. J. Gastroenterol. 2007;42:1271–1274.CrossRefPubMed
25.
Zurück zum Zitat Chandrasoma P. Diagnostic atlas of gastroesophageal reflux disease. Amsterdam: Elsevier/Academic Press; 2007. Chandrasoma P. Diagnostic atlas of gastroesophageal reflux disease. Amsterdam: Elsevier/Academic Press; 2007.
26.
Zurück zum Zitat Rothstein F, Dahms B. Barrett’s esophagus in children. In: Spechler SJ, Goyal R, eds. Barrett’s Esophagus: pathophysiology, diagnosis, and management. New York: Elseiver; 1985. Rothstein F, Dahms B. Barrett’s esophagus in children. In: Spechler SJ, Goyal R, eds. Barrett’s Esophagus: pathophysiology, diagnosis, and management. New York: Elseiver; 1985.
27.
Zurück zum Zitat Smith RR, Hamilton SR, Boitnott JK, Rogers EL. The spectrum of carcinoma arising in Barrett’s esophagus. A clinicopathologic study of 26 patients. Am. J. Surg. Pathol. 1984;8:563–573.CrossRefPubMed Smith RR, Hamilton SR, Boitnott JK, Rogers EL. The spectrum of carcinoma arising in Barrett’s esophagus. A clinicopathologic study of 26 patients. Am. J. Surg. Pathol. 1984;8:563–573.CrossRefPubMed
28.
Zurück zum Zitat Riddell RH, Odze RD. Definition of Barrett’s esophagus: time for a rethink—Is intestinal metaplasia dead? Am. J. Gastroenterol. 2009;104:2588–2594.CrossRefPubMed Riddell RH, Odze RD. Definition of Barrett’s esophagus: time for a rethink—Is intestinal metaplasia dead? Am. J. Gastroenterol. 2009;104:2588–2594.CrossRefPubMed
29.
Zurück zum Zitat Gatenby PAC, Ramus JR, Caygill CP, Shepherd NA, Watson A. Relevance of the detection of intestinal metaplasia in non dysplastic columnar lined esophagus. Scand. J. Gastroenterol. 2008;43:524–530.CrossRefPubMed Gatenby PAC, Ramus JR, Caygill CP, Shepherd NA, Watson A. Relevance of the detection of intestinal metaplasia in non dysplastic columnar lined esophagus. Scand. J. Gastroenterol. 2008;43:524–530.CrossRefPubMed
30.
Zurück zum Zitat Sharma P, McQuaid K, Dent J, et al. A critical review of the diagnosis and management of Barrett’s esophagus: the AGA Chicago Workshop. Gastroenterology. 2004;127:310–330.CrossRefPubMed Sharma P, McQuaid K, Dent J, et al. A critical review of the diagnosis and management of Barrett’s esophagus: the AGA Chicago Workshop. Gastroenterology. 2004;127:310–330.CrossRefPubMed
31.
Zurück zum Zitat Chandrasoma P, Wickramasinghe K, Ma Y, DeMeester TR. Is intestinal metaplasia a necessary precursor lesion for adenocarcinomas of the distal esophagus, gastroesophageal junction and gastric cardia? Dis. Esophagus. 2007;20:36–41.CrossRefPubMed Chandrasoma P, Wickramasinghe K, Ma Y, DeMeester TR. Is intestinal metaplasia a necessary precursor lesion for adenocarcinomas of the distal esophagus, gastroesophageal junction and gastric cardia? Dis. Esophagus. 2007;20:36–41.CrossRefPubMed
32.
Zurück zum Zitat Chandrasoma P, Wijetunge S, DeMeester S, et al. Columnar-lined esophagus without intestinal metaplasia has no proven risk of adenocarcinoma. Am. J. Surg. Pathol. 2012;36:1–7.CrossRefPubMed Chandrasoma P, Wijetunge S, DeMeester S, et al. Columnar-lined esophagus without intestinal metaplasia has no proven risk of adenocarcinoma. Am. J. Surg. Pathol. 2012;36:1–7.CrossRefPubMed
33.
Zurück zum Zitat Levine DS, Haggitt RC, Blount PL, et al. An endoscopic biopsy protocol can differentiate high-grade dysplasia from early adenocarcinoma in Barrett’s esophagus. Gastroenterology. 1993;105:40–50.CrossRefPubMed Levine DS, Haggitt RC, Blount PL, et al. An endoscopic biopsy protocol can differentiate high-grade dysplasia from early adenocarcinoma in Barrett’s esophagus. Gastroenterology. 1993;105:40–50.CrossRefPubMed
34.
Zurück zum Zitat Kariv R, Plesec T, Goldblum J, et al. The seattle protocol does not more reliably predict the detection of cancer at the time of esophagectomy than a less intensive surveillance protocol. Clin. Gastroenterol. Hepatol. 2009;7:653–658.CrossRefPubMed Kariv R, Plesec T, Goldblum J, et al. The seattle protocol does not more reliably predict the detection of cancer at the time of esophagectomy than a less intensive surveillance protocol. Clin. Gastroenterol. Hepatol. 2009;7:653–658.CrossRefPubMed
35.
Zurück zum Zitat Ishaq S, Harper E, Brown J. Survey of current clinical practice in the diagnosis, management and surveillance of Barrett’s metaplasia: a UK national survey. Gut. 2003;53:A32. Ishaq S, Harper E, Brown J. Survey of current clinical practice in the diagnosis, management and surveillance of Barrett’s metaplasia: a UK national survey. Gut. 2003;53:A32.
36.
Zurück zum Zitat Das D, Ishaq S, Harrison R, et al. Management of Barrett’s esophagus in the UK: overtreated and underbiopsied but improved by the introduction of a national randomized trial. Am. J. Gastroenterol. 2008;103:1079–1089.CrossRefPubMed Das D, Ishaq S, Harrison R, et al. Management of Barrett’s esophagus in the UK: overtreated and underbiopsied but improved by the introduction of a national randomized trial. Am. J. Gastroenterol. 2008;103:1079–1089.CrossRefPubMed
37.
Zurück zum Zitat Abrams JA, Kapel RC, Lindberg GM, et al. Adherence to biopsy guidelines for Barrett’s esophagus surveillance in the community setting in the United States. Clin. Gastroenterol. Hepatol. 2009;7:736–742.CrossRefPubMedPubMedCentral Abrams JA, Kapel RC, Lindberg GM, et al. Adherence to biopsy guidelines for Barrett’s esophagus surveillance in the community setting in the United States. Clin. Gastroenterol. Hepatol. 2009;7:736–742.CrossRefPubMedPubMedCentral
38.
Zurück zum Zitat Bennett C, Moayyedi P, Corley DA, et al. BOB CAT: a large-scale review and Delphi consensus for management of Barrett’s Esophagus with no dysplasia, indefinite for, or low-grade dysplasia. Am. J. Gastroenterol. 2015;110:662–682.CrossRefPubMedPubMedCentral Bennett C, Moayyedi P, Corley DA, et al. BOB CAT: a large-scale review and Delphi consensus for management of Barrett’s Esophagus with no dysplasia, indefinite for, or low-grade dysplasia. Am. J. Gastroenterol. 2015;110:662–682.CrossRefPubMedPubMedCentral
39.
Zurück zum Zitat Schlemper RJ, Kato Y, Stolte M. Review of histological classifications of gastrointestinal epithelial neoplasia: differences in diagnosis of early carcinomas between Japanese and Western pathologists. J. Gastroenterol. 2001;36:445–456.CrossRefPubMed Schlemper RJ, Kato Y, Stolte M. Review of histological classifications of gastrointestinal epithelial neoplasia: differences in diagnosis of early carcinomas between Japanese and Western pathologists. J. Gastroenterol. 2001;36:445–456.CrossRefPubMed
40.
Zurück zum Zitat Desai TK, Krishnan K, Samala N, et al. The incidence of oesophageal adenocarcinoma in non-dysplastic Barrett’s oesophagus: a meta-analysis. Gut. 2012;61:970–976.CrossRefPubMed Desai TK, Krishnan K, Samala N, et al. The incidence of oesophageal adenocarcinoma in non-dysplastic Barrett’s oesophagus: a meta-analysis. Gut. 2012;61:970–976.CrossRefPubMed
41.
Zurück zum Zitat Moayyedi P, Burch N, Akhtar-Danesh N, et al. Mortality rates in patients with Barrett’s oesophagus. Aliment. Pharmacol. Ther. 2008;27:316–320.CrossRefPubMed Moayyedi P, Burch N, Akhtar-Danesh N, et al. Mortality rates in patients with Barrett’s oesophagus. Aliment. Pharmacol. Ther. 2008;27:316–320.CrossRefPubMed
42.
Zurück zum Zitat Wani S, Falk GW, Post J, et al. Risk factors for progression of low-grade dysplasia in patients with Barrett’s esophagus. Gastroenterology. 2011;141:1179–1186, 1186 e1.CrossRefPubMed Wani S, Falk GW, Post J, et al. Risk factors for progression of low-grade dysplasia in patients with Barrett’s esophagus. Gastroenterology. 2011;141:1179–1186, 1186 e1.CrossRefPubMed
43.
Zurück zum Zitat Fountoulakis A, Zafirellis KD, Dolan K, Dexter SP, Martin IG, Sue-Ling HM. Effect of surveillance of Barrett’s oesophagus on the clinical outcome of oesophageal cancer. Br. J. Surg. 2004;91:997–1003.CrossRefPubMed Fountoulakis A, Zafirellis KD, Dolan K, Dexter SP, Martin IG, Sue-Ling HM. Effect of surveillance of Barrett’s oesophagus on the clinical outcome of oesophageal cancer. Br. J. Surg. 2004;91:997–1003.CrossRefPubMed
44.
Zurück zum Zitat Sonnenberg A, Soni A, Sampliner R. Medical decision analysis of endoscopic surveillance of Barrett’s oesophagus to prevent oesophageal adenocarcinoma. Aliment. Pharmacol. Ther. 2002;16:41–50.CrossRefPubMed Sonnenberg A, Soni A, Sampliner R. Medical decision analysis of endoscopic surveillance of Barrett’s oesophagus to prevent oesophageal adenocarcinoma. Aliment. Pharmacol. Ther. 2002;16:41–50.CrossRefPubMed
45.
Zurück zum Zitat Kastelein F, van Olphen S, Steyerberg E, et al. Surveillance in patients with long-segment Barrett’s oesophagus: a cost-effectiveness analysis. Gut. 2014;64:864–871.CrossRefPubMed Kastelein F, van Olphen S, Steyerberg E, et al. Surveillance in patients with long-segment Barrett’s oesophagus: a cost-effectiveness analysis. Gut. 2014;64:864–871.CrossRefPubMed
46.
Zurück zum Zitat Macdonald CE, Wicks AC, Playford RJ. Final results from 10 year cohort of undergoing surveillance for Barrett’s oesophagus: observational study. BMJ. 2000;321:1252–1255.CrossRefPubMedPubMedCentral Macdonald CE, Wicks AC, Playford RJ. Final results from 10 year cohort of undergoing surveillance for Barrett’s oesophagus: observational study. BMJ. 2000;321:1252–1255.CrossRefPubMedPubMedCentral
47.
Zurück zum Zitat Corley D, Mehtani K, Quesenberry C, Zhao W, de Boer J, Weiss N. Impact of endoscopic surveillance on mortality from Barrett’s Esophagus-associated esophageal adenocarcinomas. Gastroenterology. 2013;145:312–319.e1.CrossRefPubMedPubMedCentral Corley D, Mehtani K, Quesenberry C, Zhao W, de Boer J, Weiss N. Impact of endoscopic surveillance on mortality from Barrett’s Esophagus-associated esophageal adenocarcinomas. Gastroenterology. 2013;145:312–319.e1.CrossRefPubMedPubMedCentral
48.
Zurück zum Zitat Bhat S, Coleman H, Yousef F, et al. Risk of malignant progression in Barrett’s Esophagus patients: results from a large population-based study. J. Natl. Cancer Inst. 2011;103:1049–1057.CrossRefPubMedPubMedCentral Bhat S, Coleman H, Yousef F, et al. Risk of malignant progression in Barrett’s Esophagus patients: results from a large population-based study. J. Natl. Cancer Inst. 2011;103:1049–1057.CrossRefPubMedPubMedCentral
49.
Zurück zum Zitat Cooper SC, El-agib A, Dar S, et al. Endoscopic surveillance for Barrett’s oesophagus: the patients’ perspective. Eur. J. Gastroenterol. Hepatol. 2009;21:850–854.CrossRefPubMed Cooper SC, El-agib A, Dar S, et al. Endoscopic surveillance for Barrett’s oesophagus: the patients’ perspective. Eur. J. Gastroenterol. Hepatol. 2009;21:850–854.CrossRefPubMed
Metadaten
Titel
Diagnosis and Surveillance of Barrett’s Esophagus: Addressing the Transatlantic Divide
verfasst von
Saad Ghaus
Helmut Neumann
Humayun Muhammad
Gian Eugenio Tontini
Sauid Ishaq
Publikationsdatum
01.04.2016
Verlag
Springer US
Erschienen in
Digestive Diseases and Sciences / Ausgabe 8/2016
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-016-4138-x

Weitere Artikel der Ausgabe 8/2016

Digestive Diseases and Sciences 8/2016 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.